Best Practices for Evaluating Cognition in Parkinson’s Disease Clinical Trials
March 19, 2019 - Toronto ON CAXtalks
fbonilla@xtalks.com
Phone:1 416.977.6555
The past two decades have seen multiple industry trials explore the impact of drug treatments (primarily dopaminergic therapies and cholinesterase inhibitors) on cognition in Parkinson’s disease (PD) and PD dementia (PDD).
This website uses cookies to ensure you get the best experience on our website. Learn more